BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 30695864)

  • 21. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
    Ye H; Qin S; Li N; Lin M; Xu Y; Li X
    Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
    Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
    Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
    Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
    Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
    Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TFE3 translocation and protein expression in renal cell carcinoma are correlated with poor prognosis.
    Lee HJ; Shin DH; Kim SY; Hwang CS; Lee JH; Park WY; Choi KU; Kim JY; Lee CH; Sol MY; Rha SH; Park SW
    Histopathology; 2018 Nov; 73(5):758-766. PubMed ID: 29968390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
    Kuthi L; Somorácz Á; Micsik T; Jenei A; Hajdu A; Sejben I; Imre D; Pósfai B; Kóczián K; Semjén D; Bajory Z; Kulka J; Iványi B
    Pathol Oncol Res; 2020 Oct; 26(4):2123-2133. PubMed ID: 31955345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
    Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
    Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
    Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey.
    Akgul M; Williamson SR; Ertoy D; Argani P; Gupta S; Caliò A; Reuter V; Tickoo S; Al-Ahmadie HA; Netto GJ; Hes O; Hirsch MS; Delahunt B; Mehra R; Skala S; Osunkoya AO; Harik L; Rao P; Sangoi AR; Nourieh M; Zynger DL; Smith SC; Nazeer T; Gumuskaya B; Kulac I; Khani F; Tretiakova MS; Vakar-Lopez F; Barkan G; Molinié V; Verkarre V; Rao Q; Kis L; Panizo A; Farzaneh T; Magers MJ; Sanfrancesco J; Perrino C; Gondim D; Araneta R; So JS; Ro JY; Wasco M; Hameed O; Lopez-Beltran A; Samaratunga H; Wobker SE; Melamed J; Cheng L; Idrees MT
    J Clin Pathol; 2021 May; 74(5):291-299. PubMed ID: 33514585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
    Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
    [No Abstract]   [Full Text] [Related]  

  • 36. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
    Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.
    Mir MC; Trilla E; de Torres IM; Panizo A; Zlotta AR; Van Rhijn B; Morote J
    BJU Int; 2011 Jul; 108(2 Pt 2):E71-6. PubMed ID: 21070573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
    Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
    Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult renal cell carcinoma with rhabdoid differentiation: incidence and clinicopathologic features in Chinese patients.
    Yang X; Xi C; Jin J; Zhou L; Su J; Liu L; Liu Y
    Ann Diagn Pathol; 2015 Apr; 19(2):57-63. PubMed ID: 25708024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.